
MetaVia Inc. (NASDAQ:MTVA – Free Report) – Research analysts at HC Wainwright issued their Q1 2027 earnings estimates for MetaVia in a report issued on Tuesday, November 17th. HC Wainwright analyst A. Ghosh expects that the company will post earnings per share of ($0.82) for the quarter. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for MetaVia’s current full-year earnings is ($2.52) per share. HC Wainwright also issued estimates for MetaVia’s Q2 2027 earnings at ($0.90) EPS, Q3 2027 earnings at ($0.98) EPS and Q4 2027 earnings at ($1.05) EPS.
MetaVia (NASDAQ:MTVA – Get Free Report) last released its quarterly earnings data on Friday, November 13th. The company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.04.
View Our Latest Research Report on MetaVia
MetaVia Price Performance
Shares of MTVA opened at $1.07 on Wednesday. MetaVia has a 1 year low of $0.97 and a 1 year high of $13.42. The stock has a 50 day simple moving average of $1.41 and a 200-day simple moving average of $1.59.
Key MetaVia News
Here’s some of the latest news about MTVA:
- Positive Sentiment: HC Wainwright maintained a Buy rating and forecasts that annual losses per share will narrow after peaking in 2027, from $3.77 in 2027 to $1.58 by 2030. MetaVia analyst estimates
- Negative Sentiment: Despite that longer-term improvement, HC Wainwright projects substantial losses in the coming years: $3.07 per share for 2026 and $3.77 for 2027, with a $0.72 loss forecast for Q4 2026. Those estimates point to ongoing cash- and financing-related risk. MetaVia analyst estimates
- Negative Sentiment: MetaVia received a Nasdaq notice that its stockholders’ equity was below the exchange’s listing requirement. The deficiency creates a compliance risk and may require the company to take steps to regain compliance. MetaVia Nasdaq compliance notice
MetaVia Company Profile
MetaVia, Inc. is a clinical-stage biotechnology company focused on developing treatments for cardiometabolic diseases, including obesity, metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes. The company’s pipeline includes DA-1726, an investigational dual GLP-1 and glucagon receptor agonist being studied for obesity, and DA-1241, an investigational GPR119 agonist being developed for MASH and type 2 diabetes. These candidates are experimental and have not been established as approved treatments.
Recommended Stories
- Five stocks we like better than MetaVia
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
